Financial Lp Hrt Sells 42,411 Shares of Profusa (NASDAQ:PFSA) Stock

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt sold 42,411 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $0.89, for a total transaction of $37,745.79. Following the completion of the transaction, the insider directly owned 74,198 shares of the company’s stock, valued at $66,036.22. This trade represents a 36.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, August 12th, Financial Lp Hrt bought 5,585 shares of Profusa stock. The shares were bought at an average price of $0.96 per share, with a total value of $5,361.60.
• On Tuesday, August 4th, Financial Lp Hrt bought 1,368 shares of Profusa stock. The shares were bought at an average cost of $0.95 per share, for a total transaction of $1,299.60.
• On Monday, August 3rd, Financial Lp Hrt purchased 14,556 shares of Profusa stock. The stock was bought at an average price of $0.96 per share, for a total transaction of $13,973.76.
• On Wednesday, July 29th, Financial Lp Hrt purchased 1,310 shares of Profusa stock. The stock was bought at an average price of $1.01 per share, for a total transaction of $1,323.10.

Profusa Trading Down 5.3%

PFSA opened at $0.90 on Friday. The firm has a market cap of $170,962.00, a price-to-earnings ratio of -0.00 and a beta of 0.52. Profusa, Inc. has a 12 month low of $0.81 and a 12 month high of $1,297.50. The stock has a fifty day moving average price of $2.73 and a 200-day moving average price of $24.89.

Profusa’s stock is set to reverse split on the morning of Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 16th.

Analyst Upgrades and Downgrades

Several research firms have commented on PFSA. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.